Humacyte annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Humacyte Capital Expenditures (CapEx) Growth & History (HUMA)
Humacyte's capital expenditures (capex) was $884,000 for fiscal 2025.
View full Humacyte company overviewHumacyte annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $884,000 | −$688,000 | −43.77% |
| 2024 | 2024-12-31 | $1.6M | −$708,000 | −31.05% |
| 2023 | 2023-12-31 | $2.3M | $1.2M | +117.56% |
| 2022 | 2022-12-31 | $1.0M | $828,000 | +376.36% |
| 2021 | 2021-12-31 | $220,000 | −$98,000 | −30.82% |
| 2020 | 2020-12-31 | $318,000 | — | — |
Humacyte quarterly capital expenditures (capex)
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $104,000 | −$464,000 | −81.69% |
| Q1 2026 | 2026-03-31 | $175,000 | −$53,000 | −23.25% |
| Q4 2025 | 2025-12-31 | $39,000 | −$24,000 | −38.10% |
| Q3 2025 | 2025-09-30 | $49,000 | −$885,000 | −94.75% |
| Q2 2025 | 2025-06-30 | $568,000 | $384,000 | +208.70% |
| Q1 2025 | 2025-03-31 | $228,000 | −$163,000 | −41.69% |
| Q4 2024 | 2024-12-31 | $63,000 | −$87,000 | −58.00% |
| Q3 2024 | 2024-09-30 | $934,000 | $441,000 | +89.45% |
| Q2 2024 | 2024-06-30 | $184,000 | −$301,000 | −62.06% |
| Q1 2024 | 2024-03-31 | $391,000 | −$761,000 | −66.06% |
| Q4 2023 | 2023-12-31 | $150,000 | −$531,000 | −77.97% |
| Q3 2023 | 2023-09-30 | $493,000 | $282,000 | +133.65% |
| Q2 2023 | 2023-06-30 | $485,000 | $351,000 | +261.94% |
| Q1 2023 | 2023-03-31 | $1.2M | $1.1M | +5136.36% |
| Q4 2022 | 2022-12-31 | $681,000 | $636,000 | +1413.33% |
| Q3 2022 | 2022-09-30 | $211,000 | $128,000 | +154.22% |
| Q2 2022 | 2022-06-30 | $134,000 | $71,000 | +112.70% |
| Q1 2022 | 2022-03-31 | $22,000 | −$7,000 | −24.14% |
| Q4 2021 | 2021-12-31 | $45,000 | — | — |
| Q3 2021 | 2021-09-30 | $83,000 | — | — |
| Q2 2021 | 2021-06-30 | $63,000 | — | — |
| Q1 2021 | 2021-03-31 | $29,000 | — | — |
Humacyte capital expenditures (capex) trends
Over the last five fiscal years, Humacyte's capital expenditures (capex) increased from $318,000 to $884,000, a change of $566,000. The latest reported quarter, Q2 2026, shows $104,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Humacyte source filings ↗